SI3004155T1 - Peptidna spojina - Google Patents

Peptidna spojina

Info

Publication number
SI3004155T1
SI3004155T1 SI201431933T SI201431933T SI3004155T1 SI 3004155 T1 SI3004155 T1 SI 3004155T1 SI 201431933 T SI201431933 T SI 201431933T SI 201431933 T SI201431933 T SI 201431933T SI 3004155 T1 SI3004155 T1 SI 3004155T1
Authority
SI
Slovenia
Prior art keywords
peptide compound
peptide
compound
Prior art date
Application number
SI201431933T
Other languages
English (en)
Inventor
Taiji Asami
Ayumu Niida
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of SI3004155T1 publication Critical patent/SI3004155T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
SI201431933T 2013-05-28 2014-05-27 Peptidna spojina SI3004155T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013111893 2013-05-28
EP14729976.2A EP3004155B1 (en) 2013-05-28 2014-05-27 Peptide compound
PCT/JP2014/002772 WO2014192284A1 (en) 2013-05-28 2014-05-27 Peptide compound

Publications (1)

Publication Number Publication Date
SI3004155T1 true SI3004155T1 (sl) 2022-02-28

Family

ID=50942304

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201431933T SI3004155T1 (sl) 2013-05-28 2014-05-27 Peptidna spojina

Country Status (36)

Country Link
US (2) US10087229B2 (sl)
EP (1) EP3004155B1 (sl)
JP (2) JP6429799B2 (sl)
KR (1) KR102229051B1 (sl)
CN (1) CN105209485B (sl)
AP (1) AP2015008781A0 (sl)
AR (1) AR096440A1 (sl)
AU (1) AU2014272500B2 (sl)
CA (1) CA2908581C (sl)
CL (1) CL2015003031A1 (sl)
CY (1) CY1124790T1 (sl)
DK (1) DK3004155T3 (sl)
DO (1) DOP2015000261A (sl)
EA (2) EA035813B1 (sl)
EC (1) ECSP15044389A (sl)
ES (1) ES2900744T3 (sl)
GE (1) GEP201706762B (sl)
HK (1) HK1216757A1 (sl)
HR (1) HRP20212014T1 (sl)
HU (1) HUE057361T2 (sl)
IL (1) IL242005B (sl)
LT (1) LT3004155T (sl)
MA (1) MA38472B1 (sl)
MX (2) MX2015015464A (sl)
MY (1) MY172744A (sl)
PE (1) PE20151770A1 (sl)
PH (1) PH12015502391A1 (sl)
PL (1) PL3004155T3 (sl)
PT (1) PT3004155T (sl)
SG (1) SG11201507934PA (sl)
SI (1) SI3004155T1 (sl)
TN (1) TN2015000451A1 (sl)
TW (1) TWI638831B (sl)
UA (1) UA118558C2 (sl)
UY (1) UY35589A (sl)
WO (1) WO2014192284A1 (sl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20212014T1 (hr) 2013-05-28 2022-04-01 Takeda Pharmaceutical Company Limited Spoj peptida
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
CN104846061A (zh) * 2015-05-07 2015-08-19 中国药科大学 一种glp-1受体激动剂的受体亲和力测定方法
CN105388239B (zh) * 2015-12-18 2018-01-05 兆科药业（合肥）有限公司 一种多肽固相合成的监测方法
WO2017204219A1 (ja) * 2016-05-24 2017-11-30 武田薬品工業株式会社 ペプチド化合物
WO2018104263A1 (en) 2016-12-06 2018-06-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
JOP20180028A1 (ar) * 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
WO2019140030A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
WO2019147650A1 (en) * 2018-01-23 2019-08-01 Gila Therapeutics, Inc. Peptide yy pharmaceutical formulations, compositions, and methods
KR102379958B1 (ko) 2018-05-04 2022-04-01 노보 노르디스크 에이/에스 Gip 유도체 및 이의 용도
CN110818771B (zh) * 2018-08-14 2023-01-17 陈铭 使用氨基酸离子液体的羰基硫介导多肽合成
JP2022500483A (ja) * 2018-09-24 2022-01-04 武田薬品工業株式会社 Ｇｉｐ受容体アゴニストペプチド化合物及びその使用
US20220135638A1 (en) * 2018-09-24 2022-05-05 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
AU2020334993B2 (en) * 2019-08-19 2023-07-13 Eli Lilly And Company Methods of making incretin analogs
KR20210040818A (ko) 2019-10-04 2021-04-14 한미약품 주식회사 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도
CN110684082B (zh) 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
MX2022011816A (es) * 2020-03-25 2022-10-10 Takeda Pharmaceuticals Co Dosificacion qd de compuestos peptidicos agonistas del receptor de gip y sus usos.
MX2023000303A (es) 2020-07-22 2023-02-09 Novo Nordisk As Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral.
EP4185606A1 (en) 2020-07-22 2023-05-31 Novo Nordisk A/S Glp-1 and gip receptor co-agonists
CA3222051A1 (en) 2021-06-01 2022-12-08 Nanjing Zhihe Medicine Technology Co., Ltd. Polypeptide derivative having effect of dual targeted activation of glp-1r and gipr, preparation method therefor, and use thereof
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
CN117402219A (zh) * 2022-07-13 2024-01-16 杭州中美华东制药有限公司 Glp-1/gip双激动剂及其制备方法和用途
WO2024059674A1 (en) 2022-09-15 2024-03-21 Eli Lilly And Company Gip and glp-1 dual agonist compounds

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
DE69732572T2 (de) 1996-11-12 2005-12-29 Novo Nordisk A/S Verwendung von glp-1 peptiden
AU3087599A (en) 1998-03-19 1999-10-11 Bionebraska, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
AU5027299A (en) 1998-07-31 2000-02-28 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
HUP0104579A3 (en) 1998-12-07 2002-05-28 Univ Tulane Glp-1 analogues, pharmaceutical compositions comprising thereof and their use
CA2417590C (en) 2000-05-16 2009-08-11 Sanwa Kagaku Kenkyusho Co., Ltd Prophylactic or ameliorative agent for insulin resistance and/or obesity
CA2490564A1 (en) 2002-07-04 2004-01-15 Zealand Pharma A/S Glp-1 and methods for treating diabetes
CA2551039C (en) 2003-12-16 2013-01-29 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Analogues of glp-1
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
EP2390264A1 (en) 2005-02-11 2011-11-30 Amylin Pharmaceuticals Inc. GIP analog and hybrid polypeptides with selectable propperties
WO2006136374A2 (en) 2005-06-20 2006-12-28 Develogen Aktiengesellschaft Use of gip and/or vitamin d3 analogues thereof for enhancing stem or progenitor cell differentiation into insulin producing cells
JP2009542813A (ja) 2006-07-11 2009-12-03 ハルクネスス プハルマセウティカルス，インコーポレイテッド 飽食因子を使用して肥満を治療する方法
JP5399244B2 (ja) 2006-08-17 2014-01-29 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 選択可能な特性を持つｄｐｐ−ｉｖ耐性ｇｉｐハイブリッドポリペプチド
TWI430806B (zh) 2006-09-13 2014-03-21 Smithkline Beecham Corp 用於投與長效降血糖藥劑之方法
EP1972349A1 (en) * 2007-03-21 2008-09-24 Biocompatibles UK Limited GLP-1 fusion peptides conjugated to polymer(s), their production and use
WO2009067268A1 (en) 2007-11-23 2009-05-28 Michael Rothkopf Methods of enhancing diabetes resolution
SG192405A1 (en) 2008-06-17 2013-08-30 Univ Indiana Res & Tech Corp Gip-based mixed agonists for treatment of metabolic disorders and obesity
AU2009280021B2 (en) * 2008-08-07 2012-10-04 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal
PL2373681T3 (pl) 2008-12-10 2017-07-31 Glaxosmithkline Llc Kompozycje farmaceutyczne albiglutydu
SG176858A1 (en) * 2009-06-16 2012-02-28 Univ Indiana Res & Tech Corp Gip receptor-active glucagon compounds
JP5767582B2 (ja) 2009-07-02 2015-08-19 武田薬品工業株式会社 ペプチド及びその用途
EP2528618A4 (en) * 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
CN103402536A (zh) 2010-12-22 2013-11-20 马克迪亚生物科技公司 用gip和glp-1受体活性的基于胰高血糖素的肽来治疗代谢异常和肥胖的方法
US9790262B2 (en) 2011-04-05 2017-10-17 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
JP5914641B2 (ja) * 2011-06-10 2016-05-11 ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． グルコース依存性インスリン分泌刺激ポリペプチドのアナログ、医薬組成物及びその使用
JP2014519509A (ja) 2011-06-10 2014-08-14 ノヴォ ノルディスク アー／エス ポリペプチド
WO2013003449A2 (en) 2011-06-27 2013-01-03 Phasebio Pharmaceuticals, Inc. Methods of treatment with glp-1 receptor agonists
ES2626013T3 (es) 2011-09-06 2017-07-21 Novo Nordisk A/S Derivados de GLP-1
WO2013148117A1 (en) 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
AR090937A1 (es) 2012-05-03 2014-12-17 Zealand Pharma As Compuestos agonista duales de gip-glp-1 y metodos para usarlos
US10000542B2 (en) 2012-05-08 2018-06-19 Novo Nordisk A/S Double-acylated GLP-1 derivatives
US20150182461A1 (en) 2012-06-19 2015-07-02 Massachussets Institute Of Technology Mass Production and Size Control of Nanoparticles Through Controlled Microvortices
CA2877358A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
KR20150039748A (ko) 2012-06-21 2015-04-13 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Gip 수용체 활성을 나타내는 글루카곤의 유사체들
CN104968674A (zh) 2012-12-19 2015-10-07 诺和诺德股份有限公司 具有胆固醇流出活性的新颖的glp-1受体激动剂
WO2014096150A1 (en) 2012-12-21 2014-06-26 Sanofi Dual glp1/gip or trigonal glp1/gip/glucagon agonists
CA2902352A1 (en) 2013-03-14 2014-09-18 Medimmune Limited Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
HRP20212014T1 (hr) 2013-05-28 2022-04-01 Takeda Pharmaceutical Company Limited Spoj peptida
CA2929107C (en) 2013-11-06 2023-09-26 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
JP2018012644A (ja) 2014-11-26 2018-01-25 武田薬品工業株式会社 ペプチド化合物

Also Published As

Publication number Publication date
LT3004155T (lt) 2021-12-27
MX2015015464A (es) 2016-03-21
PT3004155T (pt) 2021-12-22
CN105209485B (zh) 2019-12-10
US20140357552A1 (en) 2014-12-04
IL242005B (en) 2019-05-30
WO2014192284A1 (en) 2014-12-04
CA2908581C (en) 2021-07-13
US20160052988A1 (en) 2016-02-25
CL2015003031A1 (es) 2016-06-24
GEP201706762B (en) 2017-10-25
US10087229B2 (en) 2018-10-02
UY35589A (es) 2014-12-31
PL3004155T3 (pl) 2022-02-07
AR096440A1 (es) 2015-12-30
EA201591891A1 (ru) 2016-01-29
HK1216757A1 (zh) 2016-12-02
EP3004155B1 (en) 2021-11-24
KR20160010446A (ko) 2016-01-27
NZ712421A (en) 2021-04-30
KR102229051B1 (ko) 2021-03-16
DOP2015000261A (es) 2015-12-31
PE20151770A1 (es) 2015-12-11
UA118558C2 (uk) 2019-02-11
PH12015502391B1 (en) 2016-02-22
EA202090593A2 (ru) 2020-06-30
TWI638831B (zh) 2018-10-21
ECSP15044389A (es) 2017-08-31
HUE057361T2 (hu) 2022-05-28
PH12015502391A1 (en) 2016-02-22
TW201514203A (zh) 2015-04-16
AU2014272500B2 (en) 2018-03-08
HRP20212014T1 (hr) 2022-04-01
MA38472A1 (fr) 2018-01-31
BR112015027596A2 (pt) 2017-12-05
US9200051B2 (en) 2015-12-01
JP6429799B2 (ja) 2018-11-28
EA035813B1 (ru) 2020-08-14
EA202090593A3 (ru) 2020-08-31
JP6570705B2 (ja) 2019-09-04
MA38472B1 (fr) 2018-09-28
MX2019010531A (es) 2019-10-15
TN2015000451A1 (en) 2017-04-06
CY1124790T1 (el) 2022-11-25
CN105209485A (zh) 2015-12-30
MY172744A (en) 2019-12-11
ES2900744T3 (es) 2022-03-18
DK3004155T3 (da) 2022-01-03
SG11201507934PA (en) 2015-10-29
JP2018168167A (ja) 2018-11-01
EP3004155A1 (en) 2016-04-13
AU2014272500A1 (en) 2015-11-05
JP2016520511A (ja) 2016-07-14
AP2015008781A0 (en) 2015-10-31
CA2908581A1 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
HK1216757A1 (zh) 肽化合物
EP2960234A4 (en) INHIBITING COMPOUND Trk
GB201302368D0 (en) Compound
HRP20180452T1 (hr) Peptidi
EP2982674A4 (en) PYRIDINYLPYRAZOLOCHINOLINVERBINDUNG
HUE050164T2 (hu) Új négy-CTL epitóp-kapcsolt peptid
HK1211596A1 (en) Peptide
EP2947066A4 (en) PHENOXYALKYLAMINVERBINDUNG
HK1211595A1 (en) Peptide
HK1198769A1 (en) Novel peptide
GB201315130D0 (en) Peptides
GB201307331D0 (en) Compound
GB201319776D0 (en) Compound
GB201316660D0 (en) Peptides
GB201315772D0 (en) Compound
GB201300381D0 (en) Peptides
GB201305634D0 (en) Compound
GB201304250D0 (en) Compound
GB201301585D0 (en) Compound